Focal homozygous deletion of cyclin-dependent kinase inhibitor 2A (CDKN2A) is a frequent finding in EGFR amplified tumors and these, together with the EGFRvIII, are features of the classical transcriptional subtype of glioblastoma (5). The gene discussed is EGFR; the disease is glioblastoma.